China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its monoclonal antibody, SSGJ-626. This BDCA2-targeted mAb will now enter trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), indications that have already been approved for study in the United States.
SSGJ-626 specifically targets BDCA2 (blood dendritic cell antigen 2), which is primarily expressed on plasmacytoid dendritic cells (pDCs). BDCA2 plays a crucial role in regulating the immune system by inhibiting interferon production in these cells. The production of interferon alpha/beta by pDCs is recognized as a significant pathophysiological factor in SLE, making BDCA2 a promising target for intervention aimed at blocking the excessive production of interferon alpha/beta in the disease.- Flcube.com
